Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial
- DOI
- 10.1007/s10120-025-01692-w
- Published
- 2025-12-04
- Container
- Gastric Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10120-025-01692-w,
title = {Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial},
author = {Ryohei Kawabata and Daisuke Sakai and Toshio Shimokawa and Rika Kizawa and Toru Ishiguro and Hiroki Yukami and Shogen Boku and Toshifumi Yamaguchi and Shunji Endo and Toshimasa Tsujinaka and Taroh Satoh},
year = {2025},
journal = {Gastric Cancer},
doi = {10.1007/s10120-025-01692-w},
url = {https://doi.org/10.1007/s10120-025-01692-w}
}RIS
TY - JOUR TI - Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial AU - Ryohei Kawabata AU - Daisuke Sakai AU - Toshio Shimokawa AU - Rika Kizawa AU - Toru Ishiguro AU - Hiroki Yukami AU - Shogen Boku AU - Toshifumi Yamaguchi AU - Shunji Endo AU - Toshimasa Tsujinaka AU - Taroh Satoh PY - 2025 JO - Gastric Cancer DO - 10.1007/s10120-025-01692-w UR - https://doi.org/10.1007/s10120-025-01692-w ER -
APA
Kawabata, R., Sakai, D., Shimokawa, T., Kizawa, R., Ishiguro, T., Yukami, H., Boku, S., Yamaguchi, T., Endo, S., Tsujinaka, T., & Satoh, T. (2025). Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. Gastric Cancer. https://doi.org/10.1007/s10120-025-01692-w
Source records
- crossref · retrieved 2026-09-27T10:02:56.169Z